Total Value in 2020: $40,736.09M (456 deals)

Deal title Principal company Partner company Value (US$M) Start date

March

Abcellera and Lilly to develop antibodies for the treatment of COVID-19 Abcellera Biologics Inc. Eli Lilly and Co. Payment unspecified 3/12/20
Abpro Bio to develop and commercialize Abpro's ABP-100 and ABP-201 for immuno-oncology and ophthalmology in Asian markets, including greater China, Japan, and South Korea Abpro Inc. Abpro Bio Co. Ltd. $1,100.00 3/3/20
Imstem to evaluate Agex Therapeutics' IMS-001 for multiple sclerosis Agex Therapeutics Inc. Imstem Biotechnology Inc. Payment unspecified 3/20/20
Innovent to develop and commercialize Alector's AL-008 against cancer in China Alector LLC Innovent Biologics Inc. Payment unspecified 3/25/20
Gen Ilac to distribute Alnylam Pharmaceuticals' Onpattro for hereditary transthyretin-mediated amyloidosis in Turkey Alnylam Pharmaceuticals Inc. Gen Ilac Payment unspecified 3/25/20
Beijing Shenogen to develop and commercialize Alopexx's DI-Leu16-IL2 for the treatment of B-cell lymphoma in China and other parts of Asia Alopexx Oncology LLC Shenogen Pharma Group Ltd. Payment unspecified 3/4/20
Olix to use AM Chemicals’ N-acetylgalactosamine-conjugation technology to develop asymmetric small interfering molecules for liver diseases Am Chemicals LLC Olix Pharmaceuticals Inc. Payment unspecified 3/30/20
Lifemax to develop, manufacture and commercialize Amgen's AMG-820 for solid tumors, worldwide Amgen Inc. Lifemax Laboratories Inc. Payment unspecified 3/30/20
Microbiotix and AMRC to develop treatment against multidrug-resistant Gonorrhoea AMR Centre Ltd. Microbiotix Inc. Payment unspecified 3/18/20
Applied DNA to evaluate an undisclosed top-20 pharmaceutical company's linear DNA platform using linear anti-CD19 CAR-T construct Applied DNA Sciences Inc. Undisclosed Payment unspecified 3/20/20
Aptorum and Covar to investigate three repurposed drugs for COVID-19 Aptorum Group Ltd. Covar Pharmaceuticals Inc. Payment unspecified 3/30/20
Arecor extended its multiproduct collaboration with an undisclosed U.S.-based clinical-stage biotechnology company to develop liquid formulations of two novel products in oncology and a rare genetic orphan condition using Arestat technology Arecor Ltd. Undisclosed U.S.-based clinical-stage biotechnology company Payment unspecified 3/19/20
Atomwise and Bridge Biotherapeutics to discover and develop small molecules targeting Pellino proteins to treat multiple indications, including inflammation Atomwise Bridge Biotherapeutics Inc. $1,080.00 3/9/20
Vycellix and Avectas to deliver RNA immunomodulator VY-M using Solupore Avectas Ltd. Vycellix Inc. Payment unspecified 3/24/20
Novartis and BD to develop, manufacture and deliver vaccines, diagnostics and treatments for COVID-19 BD Technologies Novartis AG Payment unspecified 3/26/20
Beijing Tide and Insilico Medicine to accelerate drug discovery process applying artificial intelligence technology against cancer Beijing Tide Pharmaceutical Co. Ltd. Insilico Medicine Hong Kong Ltd. Payment unspecified 3/17/20
Biocartis Group NV and Bristol-Myers Squib Co. expanded their partnership to include registering Biocartis' Idylla MSI test in China Biocartis Group NV Bristol-Myers Squib Co. Payment unspecified 3/6/20
Maruho to develop and commercialize Biofrontera's Ameluz for all indications in East Asia and Oceania Biofrontera AG Maruho Co. Ltd. $6.67 3/3/20
Bioinvent and Skylinedx to characterize gene expression and immunological signature of tumors in patients treated with BI-1206 Bioinvent International AB Skylinedx Bv Payment unspecified 3/24/20
Heilongjiang ZBD to market and distribute Biological E's daptomycin injection (50 mg) in China Biological E Ltd. Heilongjiang ZBD Pharmaceutical Co. Ltd. $0.10 3/2/20
Pfizer and Biontech to codevelop and distribute mRNA-based vaccine, BNT-162 against COVID-19 infection Biontech SE Pfizer Inc. $748.00 3/17/20
Shanghai Fosun and Biontech to develop and commercialize COVID-19 vaccine using mRNA technology in mainland China, Hong Kong and Macau and Taiwan Biontech SE Shanghai Fosun Pharmaceutical Industry Development Co. Ltd. $135.00 3/13/20
Boqi to distribute Harmony’s Seradase Serrapeptase for COVID-19 in Southwest China Boqi International Medical Inc. Chongqing Harmony Pharmaceutical Co. Ltd. Payment unspecified 3/2/20
Astrazeneca to develop apps, algorithms, software and connected devices using Brightinsight platform Brightinsight Inc. Astrazeneca plc Payment unspecified 3/25/20
Genix Pharmaceuticals to commercialize Canagen's Flu-X for coronavirus infection worldwide Canagen Pharmaceuticals Inc. Genix Pharmaceuticals Corp. $0.08 3/24/20
Super-Pharm to purchase Canndoc's GMP medical cannabis products in Israel Canndoc Ltd. Super Pharm Ltd. Payment unspecified 3/5/20
Cellect to sign binding letter of intent to acquire all rights of Canndoc's products for the reduction of opioid usage Canndoc Ltd. Cellect Biotechnology Ltd. $18.00 3/4/20
Carna Biosciences and Bionova Pharmaceuticals to develop and commercialize BTK inhibitor, AS-1763 against blood cancer worldwide, excluding greater China Carna Biosciences Inc. Bionova Pharmaceuticals Ltd. $205.00 3/16/20
Pulmonomy to develop Cellix Bio's CLX-159 for the treatment of invasive pulmonary aspergillosis and allergic bronchopulmonary aspergillosis worldwide Cellix Bio Pvt Ltd. Pulmonomy Inc. Payment unspecified 3/6/20
Alector to use Cerveau's MK-6240 for PET scans to assess the status and progression of Neurofibrillary tangles in neurodegenerative diseases, including Alzheimer’s disease Cerveau Technologies Inc. Alector LLC Payment unspecified 3/20/20
Kissei to develop and commercialize CG Oncology's CG-0070 against bladder cancer in Japan, South Korea, Taiwan and other Asian countries except China CG Oncology Inc. Kissei Pharmaceutical Co. Ltd. $140.00 3/26/20
China Grand Pharmaceutical to develop and commercialize Chongqing's APAD for sepsis worldwide Chongqing Anti New Biotechnology China Grand Pharmaceutical $13.41 3/22/20
Arctic Vision to develop and commercialize Clearside's Xipere for macular edema associated with uveitis in China, Hong Kong, Macau, Taiwan and South Korea Clearside Biomedical Inc. Arctic Vision Shanghai Biotechnology Co. Ltd. $35.50 3/11/20
Clover to use Dynavax' TLR9 agonist adjuvant, CpG 1018 to evaluate COVID-19 vaccine Clover Biopharmaceuticals Inc. Dynavax Technologies Corp. Payment unspecified 3/24/20
Takeda to develop gene therapies using Codexis' Codeevolver technology for lysosomal storage disorders and blood factor deficiencies worldwide Codexis Inc. Takeda Pharmaceutical Co. Ltd. $130.80 3/23/20
Burke to market and supply Coeptis’ Consensi for hypertension, lower blood pressure and symptoms of osteoarthritis in the U.S. Coeptis Pharmaceuticals Inc. Burke Therapeutics LLC Payment unspecified 3/11/20
Tyligand to develop and commercialize Context's Onapristone ER for breast, endometrial and ovarian cancers in China, Hong Kong and Macau Context Therapeutics LLC Tyligand Bioscience Ltd. Payment unspecified 3/12/20
Teson to commercialize Correvio's Aggrastat for acute coronary syndrome in mainland China, Macau, excluding Taiwan and Hong Kong Correvio International Sarl Hong Kong Teson Pharma Ltd. $3.50 3/10/20
Bayer and Curadev to discover and develop small molecule sting antagonists for lung diseases, cardiovascular diseases and other inflammatory diseases Curadev Pharma Pvt Ltd. Bayer AG $277.85 3/23/20
Cytomx Therapeutics and Astellas to develop probody T-Cell engaging bispecific therapies for cancer worldwide Cytomx Therapeutics Inc. Astellas Pharma Inc. $2,580.00 3/23/20
Cytoo and Askbio to screen gene therapy candidates for muscle disorder Cytoo SA Asklepios Biopharmaceutical Inc. Payment unspecified 3/2/20
GT Biopharma and Cytovance Biologics to develop a treatment for COVID-19 using GT's Trike NK cell engager platform Cytovance Biologics LLC GT Biopharma Inc. Payment unspecified 3/10/20
3B Pharmaceuticals to develop and commercialize Debiopharm's Debio-0228 against cancer worldwide Debiopharm SA 3B Pharmaceuticals Gmbh Payment unspecified 3/25/20
Eton Pharmaceuticals to commercialize Diurnal's Alkindi Sprinkle for adrenal insufficiency in the U.S. Diurnal Ltd. Eton Pharmaceuticals Inc. $49.00 3/27/20
Dragonfly Therapeutics expanded a strategic collaboration with Merck for the development of natural killer (NK) cell engager immunotherapies for oncology to add infectious disease and immune disorders Dragonfly Therapeutics Inc. Merck & Co. Inc. $47.50 3/19/20
Emergent to manufacture Novavax's vaccine candidate for the treatment of COVID-19 infection Emergent Biosolutions Inc. Novavax Inc. Payment unspecified 3/10/20
Emergent to manufacture and develop Vaxart's oral vaccine candidate for COVID-19 Emergent Biosolutions Inc. Vaxart Inc. Payment unspecified 3/18/20
Generex and Epivax to develop peptide vaccines against corona virus infection Epivax Inc. Generex Biotechnology Corp. Payment unspecified 3/4/20
Etherna and Epivax to develop cross-strain mRNA vaccine for Covid-19 infection Etherna immunotherapies NV Epivax Inc. Payment Unspecified 3/24/20
Eureka and Lyell to develop therapies against several undisclosed solid tumor targets expressed across multiple cancer types Eureka Therapeutics Inc. Lyell Immunopharma Payment unspecified 3/17/20
Everest Medicines, Jiashan National Economic and Technological Development Zone and Jiashan SDIC to develop, manufacture and commercialize drugs in oncology, infectious diseases, cardiorenal diseases and autoimmune diseases Everest Medicines Inc. Jiashan SDIC $100.00 3/17/20
Evotec to develop Ildong’s products, including IDG-16177 using Indigo platform Evotec SE Ildong Pharmaceutical Co. Ltd. Payment unspecified 3/31/20
Takeda and Evox to develop protein replacement and mRNA therapies to treat rare diseases, including Niemann-Pick Type C disease Evox Therapeutics Ltd. Takeda Pharmaceutical Co. Ltd. $882.00 3/26/20
Immunoprecise and Evqlv to discover and develop vaccine and antibody for SARS-CoV-2 Coronavirus Evqlv Inc. Immunoprecise Antibodies Ltd. Payment unspecified 3/2/20
Hoffmann-La Roche to enter into an option to develop Forge's FG-LpxC LUNG for serious lung infections Forge Therapeutics Inc. Hoffmann-La Roche Inc. $190.50 3/25/20
Forma Therapeutics sold select hit discovery capabilities and related assets to an undisclosed biotech startup Forma Therapeutics Inc. Undisclosed biotech startup Payment unspecified 3/19/20
Polaris and Fujitsu to identify a discovery platform by combining quantum-inspired technology with quantum mechanics and molecular mechanics simulations to develop molecules against dengue Fujitsu Ltd. Polarisqb Inc. Payment unspecified 3/19/20
Mochida and Gene Techno to develop and commercialize regenerative medicine product for orphan gastrointestinal diseases, including Hirschsprung disease in Japan Gene Techno Science Co. Ltd. Mochida Pharmaceutical Co. Ltd. Payment unspecified 3/23/20
Vir Biotechnology to explore impact of Generation Bio's non-viral gene therapy technology on human monoclonal antibodies against SARS-CoV-2 Generation Bio Vir Biotechnology Inc. Payment unspecified 3/30/20
Generex Biotechnology to develop COVID-19 vaccine using Ii-Key peptide vaccine technology for Sinotek-Advocates International Industry Development Generex Biotechnology Corp. Sinotek-Advocates International Industry Development Co. Ltd. $6.00 3/2/20
Kleo and Green Cross to develop natural killer cell combination therapy against COVID-19 Green Cross Labcell Kleo Pharmaceuticals Inc. Payment unspecified 3/31/20
Kaken Pharmaceutical licensed for development a number of novel small-molecule leads for an undisclosed target identified by Hitgen Hitgen Inc. Kaken Pharmaceutical Co. Ltd. Payment unspecified 3/11/20
Eurofarma to acquire Hypera Pharma's assets in Latin America Hypera Pharma SA Eurofarma Payment unspecified 3/18/20
Ideaya and Pfizer to evaluate clinical combination of IDE-196 and Binimetinib in solid tumors Ideaya Biosciences Inc. Pfizer Inc. Payment unspecified 3/18/20
Iktos to provide artificial intelligence technology access for SRI International to advance drug discovery to treat multiple viruses, including influenza and COVID-19 Iktos SAS SRI International Payment unspecified 3/3/20
Kalbe to commercialize I-Mab's TJD-5 against solid tumor in ASEAN, MENA and Sri Lanka I-Mab Biopharma Co. Ltd. Kalbe Genexine Biologics $340.00 3/30/20
Astrazeneca to use Imaginab' CD8 Immunopet technology to accelerate the development of immunotherapies against cancers Imaginab Inc. Astrazeneca plc Payment unspecified 3/30/20
Immune Therapeutics Inc. signed a binding letter of intent to collaborate with Cytocom Inc. for the development of Lodonal and IRT-101 for use against COVID-19 Immune Therapeutics Inc. Cytocom Inc. Payment unspecified 3/20/20
Hoth Therapeutics to acquire the full licensing rights of Isoprene Pharmaceuticals' VNLG-152 retinamides (retinoic acid metabolism blocking agents) for the treatment of dermatological diseases Isoprene Pharmaceuticals Inc. Hoth Therapeutics Inc. Payment unspecified 3/30/20
Iliad to acquire Jaguar’s Mytesi royalty rights Jaguar Health Inc. Iliad Research and Trading LLC $0.35 3/5/20
Janssen Research & Development to conduct a clinical study for Evolve Biosystems' Evivo for atopic dermatitis Janssen Research & Development LLC Evolve Biosystems Inc. Payment unspecified 3/26/20
Simcere to develop and commercialize Alphamab’s KN-035 for oncology indications in mainland China Jiangsu Alphamab Biopharmaceuticals Co. Ltd. Simcere Pharmaceutical Group Payment unspecified 3/30/20
Farmacia Universal to commercialize Khiron's medical cannabis magistral preparations in Peru Khiron Life Sciences Corp. Farmacia Universal SAC Payment unspecified 3/5/20
Lonza Group to manufacture Triumvira Immunologics' TAC01-HER2 T-cell therapy for solid tumor Lonza Group AG Triumvira Immunologics Inc. Payment unspecified 3/24/20
An undisclosed company to develop LTT Bio-Pharma's LT-1001 against a new indication LTT Bio-Pharma Co. Ltd. Undisclosed Payment unspecified 3/24/20
CMC Farma to market Lumosa Therapeutics' LT-1001 to treat pain in Turkey Lumosa Therapeutics Co. Ltd. CMC Farma Payment unspecified 3/17/20
Sorrento to develop and commercialize Mabpharm’s ACE-MAB for treatment of COVID-19 in North America and Europe, excluding rest of the world, including China and Japan Mabpharm Ltd. Sorrento Therapeutics Inc. Payment unspecified 3/24/20
Mannkind and Immix Biopharma to develop dry powder formulation of a compound to treat acute respiratory distress syndrome Mannkind Corp. Immix Biopharma Inc. Payment unspecified 3/17/20
Allogene Therapeutics to use Maxcyte's flow electroporation technology and expert platform to advance AlloCAR T therapies against cancer Maxcyte Inc. Allogene Therapeutics Inc. Payment unspecified 3/24/20
MBD and Azothbio to develop cancer therapeutics using artificial intelligence modeling technology MBD Co. Ltd. Azoth Bio Inc. Payment unspecified 3/3/20
Biofrontera to enter non-binding term sheet agreement with Medac to commercialize Ameluz and BF-RhodoLED for actinic keratoses and basal cell carcinoma Medac GmbH Biofrontera AG $2.22 3/13/20
Tango Therapeutics to develop Medivir's preclinical research program Medivir AB Tango Therapeutics Inc. Payment unspecified 3/16/20
Celator to acquire assets of Merrimack's preclinical nanoliposome programs Merrimack Pharmaceuticals Inc. Celator Pharmaceuticals Inc. $2.25 3/27/20
Peptidream and Mitsubishi to form joint venture Peptigrowth to develop cell therapy, regenerative medicines and other biopharmaceuticals Mitsubishi Corp. Peptidream Inc. Payment unspecified 3/12/20
Molmed to develop and supply viral vectors for Autolus' CAR-T programs to use in clinical trials and commercialization Molmed SpA Autolus Therapeutics Ltd. Payment unspecified 3/9/20
Gedeon to develop and commercialize Myovant's Relugolix combination tablet for uterine fibroids and endometriosis in Europe, the Commonwealth of Independent States including Russia, Latin America, Australia and New Zealand Myovant Sciences Ltd. Gedeon Richter Ltd. $187.50 3/31/20
Nanoform and Orion to evaluate drugs to clinical development using Cess technology Nanoforma Finland Ltd. Orion Corp. Payment unspecified 3/9/20
Oncology Pharma extended the agreement with Nanosmart Pharmaceuticals for an additional year to use Anti-Nuclear Antibody-targeted drug delivery technologies to develop and commercialize drugs for human oncology and veterinary oncology Nanosmart Pharmaceuticals Inc. Oncology Pharma Inc. Payment unspecified 3/11/20
Plus Therapeutics to develop Nanotx Therapeutics' clinical and preclinical therapies for rare cancers, including a radiotherapeutic for glioblastoma Nanotx Therapeutics Cytori Therapeutics Inc. $137.20 3/29/20
Neurorx to conduct phase II clinical trial on Relief's RLF-100 for acute and moderate respiratory distress in COVID-19 Neurorx Inc. Relief Therapeutics Holding AG Payment unspecified 3/26/20
Neurotheryx and Cyclica to establish joint venture Nineteengale Therapeutics to identify and develop cannabinoid-inspired drugs for bipolar disorder, anxiety, and pain management Neurotheryx Canada Ltd. Cyclica Inc. Payment unspecified 3/19/20
Nicox amended the agreement with Ocumension Therapeutics to include additional rights to NCX-470 for Korea and South East Asia  Nicox SA Ocumension Therapeutics Ltd. $16.90 3/11/20
Laekna Therapeutics to develop and commercialize Novartis' anti-PD-L1 Antibody FAZ-053 worldwide against cancer Novartis AG Laekna Therapeutics Shanghai Co. Ltd. Payment unspecified 3/24/20
Otsuka Pharmaceutical to co-promote Novartis Pharma's LCZ-696 for chronic heart failure in Japan Novartis Pharma KK Otsuka Pharmaceutical Co. Ltd. $91.60 3/2/20
Serum Institute of India to use Novavax's Matrix-M vaccine adjuvant with R-21 malaria vaccine Novavax Inc. Serum Institute of India Ltd. Payment unspecified 3/11/20
Novotech to conduct clinical trials against COVID-19 with Komipharm's Panaphix in South Korea Novotech (Australia) Pty Ltd. Komipharm International Co. Ltd. Payment unspecified 3/6/20
Novotech to conduct phase II study for Algernon’s Ifenprodil in coronavirus patients Novotech (Australia) Pty Ltd. Algernon Pharmaceuticals Payment unspecified 3/19/20
Ono and Numab to discover and develop a multi-specific antibody drug candidate against cancer worldwide Numab Therapeutics AG Ono Pharmaceutical Co. Ltd. $264.70 3/30/20
Elevar to obtain worldwide rights to Apealea for cancer except in Nordics, Russia, and certain countries in Eastern Europe from Oasmia Oasmia Pharmaceutical AB Elevar Therapeutics $698.00 3/25/20
Nichi-Iko to use Ono's patents for the manufacturing and marketing of Opalmon Ono Pharmaceutical Co. Ltd. Nichi-Iko Pharmaceutical Co. Ltd. Payment unspecified 3/5/20
Open Orphan to conduct research on RSV human challenge study for European Biotech company Open Orphan plc Undisclosed European Biotech company Payment unspecified 3/6/20
Orionis and Novartis to discover and design small molecule therapeutics, using its Allo-Glue technology platform against various therapeutic areas Orionis Biosciences Inc. Novartis AG Payment unspecified 3/5/20
Juno Therapeutics to use Oxford Biomedica's Lentivector platform for the development of CAR-T and TCR-T therapies in oncology and other indications Oxford Biomedica plc Juno Therapeutics Inc. $227.00 3/18/20
Inceptua to commercialize Oxurion's Jetrea for symptomatic vitreomacular adhesion or vitreomacular traction, worldwide Oxurion NV Inceptua SA Payment unspecified 3/12/20
Sorse Technology to enter a non-binding term sheet to acquire all cannabinoid assets of Pascal Biosciences Pascal Biosciences Inc. Sorse Technology Corp. $9.75 3/10/20
Pfizer to supply Ibrance for Alphamab to conduct clinical study in combination with KN-026 against metastatic HER2-positive breast cancer Pfizer Inc. Jiangsu Alphamab Biopharmaceuticals Co. Ltd. Payment unspecified 3/27/20
Pharm-Olam to advance a clinical study of Revive's bucillamine for treatment for COVID-19 Pharm-Olam International Revive Therapeutics Ltd. Payment unspecified 3/25/20
Medigene to join the collaboration of Phio Pharmaceuticals and Helmholtz Zentrum München to develop self-delivering RNAi drugs to enhance immune cell function using Phio's Intasyl platform Phio Pharmaceuticals Corp. Medigene AG Payment unspecified 3/11/20
Recerca to develop Plasmia's technological platform for the development of nucleoside-type antiviral products against Covid-19 Plasmia Biotech Sl Recerca Clínica S.L. Payment unspecified 3/18/20
PRA Health to sign a letter of intent to conduct a phase III clinical trial for Helixmith's VM-202 against diabetic peripheral neuropathy in the U.S. PRA Health Sciences Helixmith Co. Ltd. Payment unspecified 3/25/20
Fujifilm to use Precision Nanosystems’ Nanoassemblr technology to develop and manufacture nanoparticle-based therapeutics Precision Nanosystems Inc. Fujifilm Corp. Payment unspecified 3/16/20
Akers Biosciences to develop Premas Biotech's coronavirus vaccine candidate Premas Biotech Pvt. Ltd. Akers Biosciences Inc. $2.00 3/19/20
Eisai to develop and commercialize Prism Biolab's drugs for neurological diseases Prism Pharma Co. Ltd. Eisai Co. Ltd. Payment unspecified 3/31/20
Protalix and Kirin to conduct feasibility study for the evaluation of recombinant protein using Procellex Protalix Biotherapeutics Inc. Kirin Holdings Co. Ltd. Payment unspecified 3/16/20
Pantherna and Provirex to develop and evaluate lipid-based mRNA formulations against HIV and other life-threatening viral infections Provirex Genome Editing Therapies GmbH Pantherna Therapeutics GmbH Payment unspecified 3/26/20
Redbiotech and an undisclosed pharma company to develop targeted gene therapy for the genetic disorders with BRISPR platform Redbiotec AG Undisclosed pharma company Payment unspecified 3/18/20
Regeneron and Sanofi to test arthritis drug Kevzara treat as coronavirus infection Regeneron Pharmaceuticals Inc. Sanofi SA Payment unspecified 3/10/20
Kyocera to sign memorandum of understanding to commercialize Regeneus' stem cell technologies in Japan Regeneus Pty Ltd. Kyocera Corp. $2.80 3/3/20
Ultragenyx Pharmaceutical to use Regenxbio's NAV AAV8 and AAV9 vectors for use as gene therapy treatments for an undisclosed rare metabolic disorder Regenxbio Inc. Ultragenyx Pharmaceutical Inc. $7.00 3/31/20
Aju Pharm to license Ribomic's RBM-007 against age-related macular degeneration in the territory of Korea and Southeast Asia (Singapore, Philippines, Thailand, Vietnam, Indonesia, Malaysia, Cambodia and Myanmar). Ribomic Inc. Aju Pharm Co. Ltd. $6.00 3/17/20
Forty and Rocket to conduct proof-of-concept studies for FSI-174 and magrolimab in combination with RP-L102 against Fanconi anemia Rocket Pharmaceuticals Inc. Forty Seven Inc. Payment unspecified 3/11/20
Senti Biosciences to use Roosterbio's human mesenchymal stem/stromal cell bioprocess systems, rapid product and process development platform to accelerate gene modified cell therapy for solid tumors Roosterbio Inc. Senti Biosciences Inc. Payment unspecified 3/17/20
Samsung Biologics to manufacture Stcube's STT-003 for cancer Samsung Biologics Co. Ltd. Stcube & Co. Inc. Payment unspecified 3/2/20
Ocumension to develop and commercialize Sanbio's SB-623 and MSC2 for ophthalmic diseases in greater China Sanbio Co. Ltd. Ocumension Therapeutics $71.00 3/31/20
Boehringer to develop and commercialize therapies using Saniona's ion channel technology for schizophrenia worldwide Saniona ApS Boehringer Ingelheim International GmbH $85.52 3/26/20
Biocon and Sanofi to settle patent litigation related to insulin glargine device in the U.S. Sanofi SA Biocon Ltd. Payment unspecified 3/11/20
China-based undisclosed company to develop and commercialize Sareum's SAR-20293 for the treatment of hematological cancer Sareum Holdings plc China-based undisclosed company $1.25 3/26/20
Asahi Kasei to develop, manufacture and market SBI Biotech's SBI-3150 for autoimmune diseases worldwide SBI Biotech Co. Ltd. Asahi Kasei Pharma Corp. Payment unspecified 3/19/20
Scintomics to grant North American and broad international rights of PSMA radioligand patents to Point Biopharma for targeted radiotherapy of prostate cancer Scintomics GmbH Point Biopharma Inc. Payment unspecified 3/10/20
Mabxience to develop and commercialize Shanghai Henlius' HLX-02 for cancer in Argentina, Uruguay and Paraguay Shanghai Henlius Biotech Co. Ltd. Mabxience SA $0.75 3/31/20
Shionogi and Ping An to establish a data-driven joint venture to develop new drugs Shionogi & Co. Ltd. Ping An $311.00 3/31/20
Siga to provide Tpoxx access to support Turnstone’s SKV vaccinia oncolytic viral immunotherapy platform Siga Technologies Inc. Turnstone Biologics Inc. Payment unspecified 3/2/20
Silence and Astrazeneca to discover, develop and commercialize siRNA therapies for cardiovascular, renal, metabolic and respiratory diseases Silence Therapeutics plc Astrazeneca plc $480.00 3/25/20
Sirona Biochem and Beijing Huaxi to sign letter of intent to develop and commercialize product pipeline in China and worldwide Sirona Biochem Corp. Beijing Huaxipharm Co. Ltd. Payment unspecified 3/4/20
Eli Lilly to develop and commercialize Sitryx' disease-modifying therapeutics for immuno-oncology and immuno-inflammation worldwide Sitryx Therapeutics Ltd. Eli Lilly and Co. $880.00 3/31/20
Sorrento Therapeutics and Smartpharm Therapeutics to develop gene-encoded antibody vaccine for COVID-19 Smartpharm Therapeutics Inc. Sorrento Therapeutics Inc. Payment unspecified 3/23/20
Predictive Oncology and Soluble Therapeutics to develop vaccine and drugs against Corona viruses and acute respiratory syndromes using HSC technology and artificial intelligence platform Soluble Therapeutics Predictive Oncology Inc. Payment unspecified 3/12/20
Stenocare to distribute and market Panaxia's medical cannabis products in Denmark Stenocare Panaxia Pharmaceutical Industries Ltd. Payment unspecified 3/12/20
Merck extended the research term of the collaboration's first cytokine-derivative program by one year, which includes a payment to Sutro of an undisclosed amount Sutro Biopharma Inc. Merck & Co. Inc. Payment unspecified 3/12/20
Hypera Pharma to acquire Takeda's select over-the-counter and non-core drug assets in Latin America Takeda Pharmaceutical Co. Ltd. Hypera Pharma SA $825.00 3/2/20
Sciclone to develop and commercialize Tarveda's PEN-866 against solid tumors in greater China Tarveda Therapeutics Inc. Sciclone Pharmaceuticals Inc. $84.00 3/19/20
Novimmune to develop Tiziana's TZLS-501 against coronavirus infection worldwide Tiziana Life Sciences plc Novimmune SA Payment unspecified 3/11/20
Toho Holdings to distribute Kringle Pharma's KP-100IT for acute spinal cord injury in Japan Toho Holdings Co. Ltd. Kringle Pharma Inc. Payment unspecified 3/2/20
Sanofi Pasteur and Translate Bio to collaborate on an mRNA vaccine for COVID-19 Translate Bio Inc. Sanofi Pasteur Payment unspecified 3/27/20
Biosign Technologies acquires Trek Therapeutics' Vicromax to treat COVID-19 Trek Therapeutics PBC Biosign Technologies Payment unspecified 3/24/20
Nkarta to use Trianni’s transgenic mouse platform for antibody based therapeutic discovery programs Trianni Inc. Nkarta Inc. Payment unspecified 3/10/20
Neoimmunetech to develop, and commercialize Ubix Therapeutics' three therapies against cancers and infectious diseases using Degraducer technology worldwide Ubix Therapeutics Inc. Neoimmunetech Inc. Payment unspecified 3/23/20
Advanz to acquire UCB's Alprostadil products for erectile disfunction and peripheral arterial occlusive disease in various countries UCB SA Advanz Pharma Corp. $98.00 3/6/20
Ultragenyx to grant intellectual property rights of gene therapy manufacturing technologies to Daiichi Sankyo Ultragenyx Pharmaceutical Inc. Daiichi Sankyo Co. Ltd. $225.00 3/31/20
Vir Biotechnology and Alnylam expanded their collaboration to advance RNAi Therapeutics for the Coronavirus Infections, including COVID-19 Vir Biotechnology Inc. Alnylam Pharmaceuticals Inc. Payment unspecified 3/4/20
Vir Biotechnology and Biogen to sign letter of intent to develop human monoclonal antibodies for the treatment of COVID-19 Vir Biotechnology Inc. Biogen Inc. Payment unspecified 3/12/20
Hoth Therapeutics and Voltron Therapeutics to form joint venture to conduct preclinical studies for the development of vaccine against COVID-19 Voltron Therapeutics Hoth Therapeutics Inc. Payment unspecified 3/23/20
Voluntis and Bristol-Myers Squibb to co-develop digital therapeutics to support oncology patients Voluntis SA Bristol-Myers Squibb Co. Payment unspecified 3/3/20
Windtree Therapeutics signed a binding term sheet with Lee's Pharmaceutical for the continued development of Aerosurf against preterm infants with respiratory distress syndrome Windtree Therapeutics Inc. Lee's Pharmaceutical Holdings (HK) Ltd. $3.90 3/31/20
CNS Pharmaceuticals to develop WPD's several preclinical drug candidates, including WP-1122 for viral infections, including coronavirus SARS-CoV-2 WPD Pharmaceuticals sp. z o.o. CNS Pharmaceuticals Inc. $1.00 3/23/20
Vir to use Xencor's Xtend XmAb Fc technology to develop antibodies for the treatment of COVID-19 infection Xencor Inc. Vir Biotechnology Inc. Payment unspecified 3/25/20
Zydus to develop and commercialize Xoma's anti-IL-2 monoclonal antibody in India, Brazil, Mexico and other emerging markets except Xoma's territories Xoma Corp. Zydus Cadila Ltd. Payment unspecified 3/9/20
Yissum and Cytovia to develop natural killer cells inhibitor and the tumor antigen inhibitor against blood cancers and solid tumor Yissum Research Development Co. Cytovia Therapeutics Payment unspecified 3/18/20
Hisun-Pfizer Pharmaceutical to promote Zai Lab's Omadacycline in China Zai Lab Ltd. Hisun-Pfizer Pharmaceutical Co. Ltd. $93.27 3/21/20

No Comments